CareDx (CDNA) CEO Hanna John Walter JR Sells $1.2M of Stock
CareDx President and CEO Hanna John Walter JR sold nearly 40,000 shares in a planned transaction valued at over $1.16 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Hanna John Walter JR, President and CEO at CareDx, Inc. ($CDNA), sold 39,900 shares at an average price of $29.24, worth about $1.17 million, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $CDNA is down 0.8% after 1 week, up 20.9% after 1 month and up 118.6% to date (from the $29.28 close on Jun 29, 2026).
CDNA
CareDx, Inc.
Key Points
- Hanna John Walter JR sold 39,900 shares of CareDx for about $1,166,676 on June 29, 2026, at an average price of $29.24 per share.
- The stock is currently trading around $28.50, significantly lower than its 52-week high of $55.16.
- CareDx has a market cap of approximately $2.81 billion and is set to report earnings on November 3, 2026.
Get $CDNA trade alerts by text
We text you when insiders, Congress or big funds trade $CDNA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CareDx, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at CareDx, Inc.
On June 29, 2026, CareDx, Inc. President and CEO Hanna John Walter JR sold 39,900 shares of the company, valued at approximately $1,166,676. The sale was part of a planned transaction, with shares sold at an average price of $29.24 each. This action comes shortly after he purchased 39,900 shares just three days prior on June 26 for about $327,180.
Recent Insider Activity
This sale follows other recent insider transactions by Hanna John Walter JR, which included a planned sale of 100 shares on June 26, 2026, valued at $2,900, and a sale of 17,683 shares on June 15, 2026, worth over $424,000. These transactions indicate active management of his holdings in the company.
How CareDx, Inc. Stock Has Traded
Currently, CareDx shares trade at about $28.50, significantly lower than their 52-week high of $55.16. This decline may impact investor sentiment, especially in light of the recent insider sales. Investors often keep a close eye on insider trading activity as it can signal confidence levels within a company.
Analysts Set New Price Targets
Analysts have mixed opinions about CareDx. On September 24, 2026, BTIG maintained a "Buy" rating with a price target of $74. Canaccord Genuity also initiated a "Buy" rating on September 2, 2026, with a target of $65. Meanwhile, HC Wainwright & Co. reiterated a "Neutral" rating on July 31 with a target of $46. Overall, the consensus target price among analysts is approximately $54.14, suggesting potential upside from current levels.
What CareDx, Inc. Does
CareDx, Inc. specializes in solutions for transplant patients, providing advanced diagnostics for organ health. Their products include AlloSure and AlloMap, which help monitor transplant health. The recent insider transactions could indicate a strategic adjustment amid the company's ongoing developments in the healthcare sector.
What's Ahead for CareDx, Inc.
CareDx is set to report its next earnings on November 3, 2026. Investors will be watching closely for updates on financial performance and any further insider trading activity, as it may provide insight into management's confidence in the company's future prospects. As a reminder, these insider trades reflect past transactions and may not represent current positions.
Related Filing Alerts
Source: Hanna John Walter JR's Form 4 filing on $CDNA (Jun 29, 2026). Find the original filing: CDNA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts